Centogene signs strategic transaction with private equity group charme capital partners

Cambridge, mass. and rostock, germany and berlin, nov. 13, 2024 (globe newswire) -- centogene n.v. (otc: cntgf) (“centogene” or the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a share purchase agreement (“spa”) pursuant to which its operating subsidiaries will be sold to an affiliate of charme capital partners limited (“charme”), a pan-european private equity firm, for a cash purchase price of eur 8,717,906.80. in connection with the transaction, centogene gmbh will receive funding, secured by saudi accounts receivables, from its saudi arabian joint venture genomics innovations company limited (lifera omics) (the “jv”) to provide it liquidity to the closing date, and the company shall be relieved of all existing liabilities owing to the company's senior secured lender oxford finance llc (“oxford”). the sale transaction is expected to close in the first quarter of 2025.
CNTG Ratings Summary
CNTG Quant Ranking